Invesaro

Stocks Comparison

Caris Life Sciences vs Quest Diagnostics: revenue, profit, margins and growth compared

Caris Life Sciences brought in $812M of revenue in fiscal 2025, Quest Diagnostics $11B in fiscal 2025. Revenue changed by +97.0% at Caris Life Sciences and +11.8% at Quest Diagnostics on the year before, so Caris Life Sciences grew faster. Caris Life Sciences kept -8.4% of its revenue as net profit, Quest Diagnostics 9.0%. Free cash flow was $66.9M at Caris Life Sciences and $1.4B at Quest Diagnostics.

Side by side, latest fiscal year

CAIDGX
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$812M$11B
Revenue growth+97.0%+11.8%
Net income-$68.1M$992M
Net margin-8.4%9.0%
Free cash flow$66.9M$1.4B
Free cash flow margin8.2%12.3%
Earnings per share (diluted)-$3.22$8.75
Cash$796.3M$420M
Debt$378.5M$5.7B
Price to earningsn/a27.0
Market value$9B$26.1B
Dividend yieldn/an/a
Rank by revenue in sector#161 of 523 · Health care#43 of 523 · Health care

Over the years

Revenue
CAI FY2023: $306.1MCAI FY2025: $412.3MCAI FY2025: $812MDGX FY2018: $7.5BDGX FY2019: $7.7BDGX FY2020: $9.4BDGX FY2021: $10.8BDGX FY2022: $9.9BDGX FY2023: $9.3BDGX FY2024: $9.9BDGX FY2025: $11BFY18FY19FY20FY21FY22FY23FY24FY25
CAI $812MDGX $11B
Net income
CAI FY2023: -$341.4MCAI FY2025: -$281.9MCAI FY2025: -$68.1MDGX FY2018: $736MDGX FY2019: $858MDGX FY2020: $1.4BDGX FY2021: $2BDGX FY2022: $946MDGX FY2023: $854MDGX FY2024: $871MDGX FY2025: $992MFY18FY19FY20FY21FY22FY23FY24FY25
CAI -$68.1MDGX $992M
Net margin
CAI FY2023: -111.5%CAI FY2025: -68.4%CAI FY2025: -8.4%DGX FY2018: 9.8%DGX FY2019: 11.1%DGX FY2020: 15.2%DGX FY2021: 18.5%DGX FY2022: 9.6%DGX FY2023: 9.2%DGX FY2024: 8.8%DGX FY2025: 9.0%FY18FY19FY20FY21FY22FY23FY24FY25
CAI -8.4%DGX 9.0%
Revenue growth
CAI FY2025: +34.7%CAI FY2025: +97.0%DGX FY2019: +2.6%DGX FY2020: +22.1%DGX FY2021: +14.3%DGX FY2022: -8.4%DGX FY2023: -6.4%DGX FY2024: +6.7%DGX FY2025: +11.8%FY19FY20FY21FY22FY23FY24FY25
CAI +97.0%DGX +11.8%
Free cash flow
CAI FY2023: -$298.4MCAI FY2025: -$253.6MCAI FY2025: $66.9MDGX FY2018: $817MDGX FY2019: $843MDGX FY2020: $1.6BDGX FY2021: $1.8BDGX FY2022: $1.3BDGX FY2023: $864MDGX FY2024: $909MDGX FY2025: $1.4BFY18FY19FY20FY21FY22FY23FY24FY25
CAI $66.9MDGX $1.4B

Fiscal years as each company reports them; the two may end in different months.

Questions about Caris Life Sciences and Quest Diagnostics

Which is bigger by revenue, Caris Life Sciences or Quest Diagnostics?

Quest Diagnostics is bigger by revenue: $11B in fiscal 2025, against $812M for Caris Life Sciences in fiscal 2025.

Which keeps more of its revenue as profit, Caris Life Sciences or Quest Diagnostics?

Caris Life Sciences had a net margin of -8.4% in fiscal 2025; Quest Diagnostics had 9.0% in fiscal 2025.

Which grew revenue faster, Caris Life Sciences or Quest Diagnostics?

In their latest fiscal years revenue changed by +97.0% at Caris Life Sciences and +11.8% at Quest Diagnostics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies